Fresenius Kabi and Bayer Schering Pharma extend collaboration regarding HESylation Technology

15-Jan-2010 - Germany

Fresenius Kabi Deutschland GmbH and Bayer Schering Pharma AG have extended their collaboration in the field of HESylation® Technology. The companies started their cooperation in May 2009 and now have entered into the next phase of development. The extension of the collaboration is combined with a further payment to Fresenius Kabi.

Under the Research, Development and License Agreement, Fresenius Kabi has licensed its proprietary HESylation® Technology to Bayer Schering Pharma. This technology platform is based on hydroxyethyl starch (“HES”) and may allow the prolongation of the active half-life of proteins.

Fresenius Kabi is responsible for supporting Bayer Schering Pharma with respect to implementing HESylation® Technology and providing the appropriate HES derivative to Bayer Schering Pharma. Under the agreement, Bayer Schering Pharma oversees the development and commercialization. Fresenius Kabi will receive milestone payments as well as royalties on sales for licensing of the HESylation® Technology.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance